Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET

被引:35
作者
Goudarzi, Behnaz [2 ]
Fukushima, Kenji [2 ]
Bravo, Paco [2 ]
Merrill, Jennifer [2 ]
Bengel, Frank M. [1 ,2 ]
机构
[1] Hannover Med Sch, Dept Nucl Med, D-30625 Hannover, Germany
[2] Johns Hopkins Univ, Div Nucl Med, Russell H Morgan Dept Radiol, Baltimore, MD USA
关键词
PET; Myocardial flow reserve; Pharmacological vasodilation; Regadenoson; Coronary artery disease; POSITRON-EMISSION-TOMOGRAPHY; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; SELECTIVE A(2A) AGONIST; RECEPTOR AGONIST; PROGNOSTIC VALUE; DOUBLE-BLIND; ADENOSINE; SAFETY; RESERVE;
D O I
10.1007/s00259-011-1853-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Regadenoson is a novel selective A(2A) adenosine receptor agonist, which is administered as an intravenous bolus at a fixed dose. It is currently not clear if the absolute flow increase in response to this fixed dose is a function of distribution volume in individual patients or if it is generally comparable to the previous standard agents dipyridamole or adenosine, which are dosed based on weight. We used quantitative analysis of clinical Rb-82 PET/CT studies to obtain further insights. A total of 104 subjects with normal clinical rest/stress Rb-82 perfusion PET/CT were included in a retrospective analysis. To rule out confounding factors, none had evidence of prior cardiac disease, ischaemia or infarction, cardiomyopathy, diabetes with insulin use, calcium score > 400, renal disease or other significant systemic disease. A group of 52 patients stressed with regadenoson were compared with a group of 52 patients stressed with dipyridamole before regadenoson became available. The groups were matched for clinical characteristics, risk factors and baseline haemodynamics. Myocardial blood flow (MBF) and myocardial flow reserve (MFR) were quantified using a previously validated retention model, after resampling of dynamic studies from list-mode Rb-82 datasets. At rest, heart rate, blood pressure and MBF were comparable between the groups. Regadenoson resulted in a significantly higher heart rate (34 +/- 14 vs. 23 +/- 10 beats per minute increase from baseline; p < 0.01) and rate-pressure product. Patients in the regadenoson group reported less severe symptoms and required less aminophylline. Stress MBF and MFR were not different between the groups (2.2 +/- 0.6 vs. 2.1 +/- 0.6 ml/min/g, p = 0.39, and 2.9 +/- 0.8 vs. 2.8 +/- 0.7, p = 0.31, respectively). In the regadenoson group, there was no correlation between stress flow or MFR and body weight or BMI. Despite its administration at a fixed dose, regadenoson results in an absolute increase in MBF which is comparable to that following dipyridamole administration and is independent of patient distribution volume. This further supports its usefulness as a clinical stress agent.
引用
收藏
页码:1908 / 1916
页数:9
相关论文
共 24 条
  • [1] Regadenoson: A New Myocardial Stress Agent
    Al Jaroudi, Wael
    Iskandrian, Ami E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) : 1123 - 1130
  • [2] Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT
    Bateman, TM
    Heller, GV
    McGhie, AI
    Friedman, JD
    Case, JA
    Bryngelson, JR
    Hertenstein, GK
    Moutray, KL
    Reid, K
    Cullom, SJ
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2006, 13 (01) : 24 - 33
  • [3] Cardiac Positron Emission Tomography
    Bengel, Frank M.
    Higuchi, Takahiro
    Javadi, Mehrbod S.
    Lautamaki, Riikka
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) : 1 - 15
  • [4] Reference Ranges for LVEF and LV Volumes from Electrocardiographically Gated 82Rb Cardiac PET/CT Using Commercially Available Software
    Bravo, Paco E.
    Chien, David
    Javadi, Mehrbod
    Merrill, Jennifer
    Bengel, Frank M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (06) : 898 - 905
  • [5] Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging Integrated ADVANCE-MPI Trial Results
    Cerqueira, Manuel D.
    Nguyen, Patricia
    Staehr, Peter
    Underwood, S. Richard
    Iskandrian, Ami E.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2008, 1 (03) : 307 - 316
  • [6] SAFETY PROFILE OF ADENOSINE STRESS PERFUSION IMAGING - RESULTS FROM THE ADENOSCAN-MULTICENTER-TRIAL-REGISTRY
    CERQUEIRA, MD
    VERANI, MS
    SCHWAIGER, M
    HEO, J
    ISKANDRIAN, AS
    ALAZRAKI, NP
    BEAN, LC
    BELARDINELLI, L
    BELL, M
    BERMAN, DS
    BOTVINICK, EH
    CHEIRIF, J
    HANSEN, CL
    HELLER, GV
    JOHNSTON, DL
    LEPPO, JA
    MADDAHI, J
    PARKER, LS
    MOHIUDDIN, S
    RAICHLEN, JS
    REIS, GJ
    SCHELBERT, HR
    SEALS, AA
    STOLZENBERG, J
    WILLIAMS, KA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (02) : 384 - 389
  • [7] Comparison of Measures of Left Ventricular Function from Electrocardiographically Gated 82Rb PET with Contrast-Enhanced CT Ventriculography: A Hybrid PET/CT Analysis
    Chander, Ankit
    Brenner, Michele
    Lautamaki, Riikka
    Voicu, Corina
    Merrill, Jennifer
    Bengel, Frank M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (10) : 1643 - 1650
  • [8] INFLUENCE OF AGE AND HEMODYNAMICS ON MYOCARDIAL BLOOD-FLOW AND FLOW RESERVE
    CZERNIN, J
    MULLER, P
    CHAN, S
    BRUNKEN, RC
    PORENTA, G
    KRIVOKAPICH, J
    CHEN, KW
    CHAN, A
    PHELPS, ME
    SCHELBERT, HR
    [J]. CIRCULATION, 1993, 88 (01) : 62 - 69
  • [9] Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats
    Dhalla, AK
    Wong, MY
    Wang, WQ
    Biaggioni, I
    Belardinelli, L
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02) : 695 - 702
  • [10] New technology for noninvasive evaluation of coronary artery disease
    Di Carli, Marcelo F.
    Hachamovitch, Rory
    [J]. CIRCULATION, 2007, 115 (11) : 1464 - 1480